Solventum Corporation/$SOLV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Solventum Corporation

Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.

Ticker

$SOLV
Sector
Health

Primary listing

NYSE

Employees

22,000
Headquarters
Maplewood, United States
Website
www.solventum.com

SOLV Metrics

BasicAdvanced
$12B
32.95
$2.18
-
-

What the Analysts think about SOLV

Analyst ratings (Buy, Hold, Sell) for Solventum Corporation stock.

Bulls say / Bears say

Management raised full-year 2025 organic sales growth guidance to 2.0%–3.0% and adjusted EPS to $5.80–$5.95, showing confidence in its transformation strategy and ongoing market momentum (PR Newswire)
The company achieved five straight quarters of positive sales volume growth, with Q2 net sales up 3.9% year-over-year to $2.16 billion, underlining steady demand across its range of products (PR Newswire)
Strong segment performance led MedSurg organic revenue to climb 3.9% to $1.22 billion and Health Information Systems organic revenue to rise 3.2%, demonstrating robust growth in key business areas (Investing.com)
GAAP operating margin fell to 9.9% in Q2 from 11.7% a year earlier, showing increasing pressure on margins despite higher revenue (Solventum)
Free cash flow stayed low at $59 million in Q2, even with $214 million in operating income, indicating difficulties in turning profits into cash as the company continues to invest (PR Newswire)
Corporate and unallocated expenses jumped to $182 million in Q2 from $107 million a year ago, dragging down profitability as growth spending increases (Solventum)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

SOLV Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SOLV Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

SOLV News

AllArticlesVideos
Solventum raises annual profit forecast on strength in surgical equipment

Solventum raises annual profit forecast on strength in surgical equipment

Reuters3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SOLV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs